These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10480523)

  • 1. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.
    Kilhovd BK; Berg TJ; Birkeland KI; Thorsby P; Hanssen KF
    Diabetes Care; 1999 Sep; 22(9):1543-8. PubMed ID: 10480523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
    Wautier MP; Massin P; Guillausseau PJ; Huijberts M; Levy B; Boulanger E; Laloi-Michelin M; Wautier JL
    Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.
    Berg TJ; Clausen JT; Torjesen PA; Dahl-Jørgensen K; Bangstad HJ; Hanssen KF
    Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
    Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
    Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial Dysfunction and Advanced Glycation End Products in Patients with Newly Diagnosed Versus Established Diabetes: From the CORDIOPREV Study.
    de la Cruz-Ares S; Cardelo MP; Gutiérrez-Mariscal FM; Torres-Peña JD; García-Rios A; Katsiki N; Malagón MM; López-Miranda J; Pérez-Martínez P; Yubero-Serrano EM
    Nutrients; 2020 Jan; 12(1):. PubMed ID: 31963378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ellisras Longitudinal Study 2017: elevated serum levels of carboxymethyl-lysine, an advanced glycation end-product, are associated with higher odds of developing endothelial dysfunction in black South African patients with type 2 diabetes mellitus (ELS 29).
    Mogale MA; Mhlanga CM; Gololo SS; Adu A
    Cardiovasc J Afr; 2019 Jul/Aug 23; 30(4):193-197. PubMed ID: 31469381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.
    Vay D; Vidali M; Allochis G; Cusaro C; Rolla R; Mottaran E; Bellomo G; Albano E
    Diabetologia; 2000 Nov; 43(11):1385-8. PubMed ID: 11126407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA; Elewa A; Arafa LF
    Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults.
    Kizer JR; Benkeser D; Arnold AM; Ix JH; Mukamal KJ; Djousse L; Tracy RP; Siscovick DS; Psaty BM; Zieman SJ
    Atherosclerosis; 2014 Jul; 235(1):116-21. PubMed ID: 24825341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
    Berg TJ; Snorgaard O; Faber J; Torjesen PA; Hildebrandt P; Mehlsen J; Hanssen KF
    Diabetes Care; 1999 Jul; 22(7):1186-90. PubMed ID: 10388987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.
    Takeuchi M; Makita Z; Yanagisawa K; Kameda Y; Koike T
    Mol Med; 1999 Jun; 5(6):393-405. PubMed ID: 10415164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study.
    Luft VC; Duncan BB; Schmidt MI; Chambless LE; Pankow JS; Hoogeveen RC; Couper DJ; Heiss G
    Diabet Med; 2016 Oct; 33(10):1392-8. PubMed ID: 26359784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end products and coronary heart disease in type 2 diabetes.
    Poirier P; Eckel RH
    Diabetes Care; 2000 Sep; 23(9):1441-2. PubMed ID: 10977055
    [No Abstract]   [Full Text] [Related]  

  • 16. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
    O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
    J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.
    Wagner Z; Wittmann I; Mazák I; Schinzel R; Heidland A; Kientsch-Engel R; Nagy J
    Am J Kidney Dis; 2001 Oct; 38(4):785-91. PubMed ID: 11576882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease.
    Sakata N; Imanaga Y; Meng J; Tachikawa Y; Takebayashi S; Nagai R; Horiuchi S
    Atherosclerosis; 1999 Jan; 142(1):67-77. PubMed ID: 9920507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus.
    van Deutekom AW; Niessen HW; Schalkwijk CG; Heine RJ; Simsek S
    Eur J Endocrinol; 2008 May; 158(5):655-60. PubMed ID: 18426823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study.
    Linssen PB; Henry RM; Schalkwijk CG; Dekker JM; Nijpels G; Brunner-La Rocca HP; Stehouwer CD
    Diab Vasc Dis Res; 2016 Jul; 13(4):278-85. PubMed ID: 27190078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.